Verstovsek, Srdan http://orcid.org/0000-0002-6912-8569
Parasuraman, Shreekant
Yu, Jingbo
Shah, Anne
Kumar, Shambhavi
Xi, Ann
Harrison, Claire
Funding for this research was provided by:
Incyte Corporation
Article History
Received: 14 September 2021
Accepted: 26 September 2021
First Online: 9 October 2021
Declarations
:
: The study did not require approval from an institutional review board, as all analyzed data were from secondary sources and no personally identifying information was collected or reported.
: Informed consent was not required owing to the retrospective study design.
: Not applicable. No personally identifying information was collected or reported.
: SV received research support from AstraZeneca, Blueprint Medicines Corp, Celgene, CTI BioPharma Corp, Genentech, Gilead, Incyte Corporation, ItalPharma, Novartis, NS Pharma, PharmaEssentia, Promedior, Protagonist Therapeutics, Roche, and Sierra Oncology; and is a paid consultant for Celgene, Incyte Corporation, Novartis, and Sierra Oncology. SP and JY are employees and shareholders of Incyte Corporation. AS, SK, and AX are employees of Avalere Health, a paid consultant of Incyte Corporation. CH served on speakers bureaus for Celgene, CTI BioPharma Corp, Gilead Sciences, Incyte Corporation, Janssen, Novartis, and Shire; has received research funding (institutional) from Celgene and Novartis; and has received honoraria from AOP Orphan Pharmaceuticals, Celgene, CTI BioPharma Corp, Gilead Sciences, Novartis, Promedior, Roche, Shire, and Sierra Oncology.